Acute Agitation and Aggression Treatment Market Size, Share, Growth, Sales, Revenue, Consumption, Trends, Company Analysis and Forecast 2020-2027

According to Vision Research Reports, the global acute agitation and aggression treatment market size surpassed US$ 3 Bn in 2019 and is projected to expand US$ 4.5 billion by 2027 with a CAGR of 5.2% from 2020 to 2027.

Increase in the diagnosis of agitation and aggression in psychological illnesses, establishment of organizations to spread awareness, and rise in economic burden of psychological illness contribute to the growth of the global acute agitation and aggression treatment market.

Agitation can be defined as excessive motor or verbal behavior, which can escalate to aggression. Physical agitation and aggression manifest in the form of throwing objects toward people, and verbal agitation and aggression manifest as abuses and threats. Acute agitation and aggression is one of the common symptoms in various mental illnesses, including schizophrenia, dementia, bipolar disorder, alcohol withdrawal, and depression. 

Opportunity Analysis for Market Players

As awareness about the condition and its long-term effect increases, there has been an exponential growth in the number of patients receiving medical help for acute agitation and aggression, which has intensified the competitiveness of the landscape. In order to stay ahead of the curve, market players make heavy investments in research & development activities to increase the exclusiveness of their product portfolios, and Ono Pharmaceuticals Co., Ltd has implemented the same strategy. The company inaugurated a new research center for strengthening its development and manufacturing capabilities of novel drugs for the treatment of mental illnesses.

Additionally, in order to introduce novel treatments, research activities on lithium, cannabinoids, analgesics, narcotics, and non-steroidal anti-inflammatory drugs, as well as newer antiepileptic drugs are ongoing at a significant pace. For instance, BXCL501, developed by BioXel Technologies, for the treatment of acute agitation and aggression condition, indicating schizophrenia, bipolar disorder, and geriatric dementia, is a pipeline drug. Another player, H. Lundbeck A/S, accounts for the development of Rexulti, a pipeline drug for the treatment of agitation, indicating dementia.

Since drugs consumed for acute agitation and aggression treatment require a prescription, manufactures can zoom-in their focus on partnerships and collaborations with hospitals, ambulatory surgical centers, and psychiatric care facilities, in order to ensure the long-term supply of drugs. As the Asia Pacific acute agitation and aggression treatment market is catching up with the exponential growth pace of North America, manufacturers can devise a cost-competitive strategy to penetrate into cost-sensitive markets. All-in-all, drug manufacturers can look at steady growth of the acute agitation and aggression treatment market during the forecast period.

Spreading Awareness about Agitation & Aggression and Rise in Economic Burden of Psychological Illness Drive Market 

• Changing attitudes toward the diagnosis of agitation and aggression among mentally ill patients and rise in awareness about treatments boost the growth of the global acute agitation and aggression treatment market. The global acute agitation and aggression treatment market is expected to expand at a CAGR of ~ 5% from 2019 to 2027.
• A number of trends have been observed in the global acute agitation and aggression treatment market. Increase in the incidences of dementia among the geriatric population, rise in burden of mental illness, surge in agitation in patients, and increase in prescriptions of anti-psychotics are likely to contribute to the growth of the acute agitation and aggression treatment market
• Focus on research and development for the development of novel treatments for agitation and significant unmet clinical needs are likely to drive the global acute agitation and aggression treatment market. There is significant focus on research on the usage of combination drugs, which include a combination of anti-psychotic drugs and antidepressants.
• In order to address the unmet needs, acute agitation and aggression treatment market players are focused on enhancing their research and development, and strengthening their pipeline, with emphasis on the early launch of products. For instance, in 2019, Otsuka Pharmaceutical Company and Lundbeck started their phase III trial for the evaluation of Brexpiprazole, for the treatment of agitation in Alzheimer's disease patients.
• However, the social stigma associated with mental illness and preference for non-pharmacological interventions are likely to hamper the growth of the global acute agitation and aggression treatment market. 

Second-generation Anti-psychotics to Capture Major Market Share 

• The acute agitation and aggression treatment market has been segmented based on drug class, route of administration, indication, end user, and region. In terms of drug class, the global acute agitation and aggression treatment market has been categorized into first-generation anti-psychotics, second-generation anti-psychotics, benzodiazepines, and others.
• Based on indication, the global acute agitation and aggression treatment market has been classified into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. In terms of end user, the acute agitation and aggression treatment market has been divided into hospitals and ambulatory surgical centers, psychiatric care facilities, and others.
• In terms of region, the global acute agitation and aggression treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

Increase in Prescription of Anti-psychotics to Propel Acute Agitation and Aggression Treatment Market

• In terms of drug class, the second-generation anti-psychotics segment is expected to grow at a rapid pace in the acute agitation and aggression treatment market during the forecast period. Second-generation anti-psychotics, also known as atypical anti-psychotics, are a group of anti-psychotics used in the treatment of psychiatric conditions. These are also known as dopamine-serotonin antagonists. This group of drugs acts by blocking the receptors in the brain’s dopamine pathways.
• Growth of the segment can be attributed to increase in prescriptions of the drugs in this drug class for the treatment of acute agitation and aggression associated with various psychological illnesses
• Additionally, second-generation anti-psychotics have lower risk of tardive dyskinesia and extrapyramidal side effects. Moreover, these cause less severe neuromuscular side effects and fewer sexual side effects as compared to first-generation anti-psychotics. 

The Exponentially Growing End User of the Market

Marketing campaigns, as initiated by private companies, and increase in general awareness, as undertaken by central health authorities, regarding acute agitation and aggression treatment, are likely to surge the number of end users in the industry. Currently, hospitals, ambulatory surgical centers, and psychiatric care facilities, among others, account for the massive adoption of drugs and treatment procedures. However, hospital and ambulatory surgical centers show a striking RoI potential with their high concentration in developed countries and even in remote areas of developing countries. Since patients with acute agitation and aggression disorder require immediate attention and care, to further avoid the condition from worsening, intensive care units and emergency departments of hospitals are gaining high traction.

In 2019, hospitals and ambulatory surgical centers collectively accounted for ~45% of the market share, with the growth in the number of individuals seeking screening and treatment for acute agitation and aggression disorder. However, once held back on account of the dearth of skilled psychiatrists, psychiatric care facilities are witnessing exponential improvement in the number of skilled medical personnel as well as patients demanding consultations for acute agitation and aggression treatment. This is likely to stimulate the popularity of psychiatric care facilities, which are projected to record a CAGR of ~5% during the forecast period.

Asia Pacific Market to Expand at Rapid Pace

• North America held a prominent share of the global acute agitation and aggression treatment market in terms of revenue in 2019, and is projected to sustain its market share during the forecast period. Focus on spreading awareness among people about treatment related to agitation and aggression, increase in economic burden of mental illness, well-established healthcare infrastructure, presence of leading players, and rise in the focus of these players on research and development are boosting the growth of the acute agitation and aggression treatment market in North America.
• According to the National Alliance of Mental Illness, over 10.2 million adults in the U.S. suffer from mental health and addiction disorders. Moreover, over 2 in every 5 adults in the U.S. suffer from mental illness. and more than 1 in 25 adults live with a serious mental illness.
• Europe is anticipated to be the second largest market in terms of share and revenue during the forecast period. Significant number of non-government organizations focused on spreading awareness about the treatment of mental illness fuels the growth of the acute agitation and aggression treatment market in the region. The Alzheimer’s Society in the U.K., a charity organization that creates campaigns for bringing awareness regarding the signs of agitation and aggression in Alzheimer’s, funds research efforts to find a cure for the disease.
• The acute agitation and aggression treatment market in Asia Pacific is anticipated to expand at a high CAGR of 5.5% during the forecast period. Growth of the acute agitation and aggression treatment market in the region is attributed to increase in the geriatric population, rise in the prevalence of mental illness such as schizophrenia and bipolar disorder, and focus of market players on India and Japan to exploit opportunities in these emerging markets. 

Key Players

• Eli Lilly and Company
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Otsuka Holdings Co., Ltd.
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Janssen Biotech, Inc. (Johnson & Johnson)
• H. Lundbeck A/S

Market Segmentation

By Drug Class

• • First-generation Anti-psychotics
  • Second-generation Anti-psychotics
  • Benzodiazepines
  • Others

By Route of Administration

• • Oral
  • Intramuscular
  • Others

By Indication

• • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation and Aggression
  • Alcohol Withdrawal
  • Others

By End User

• • Hospitals and Ambulatory Surgical Centers
    • Intensive Care Units
    • Emergency Departments
  • Psychiatric Care Facilities
  • Others

By Region

• • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa 

Scope of the Study

Vision Research Reports conducted a comprehensive assessment regarding the growth potential of the acute agitation and aggression treatment market, in its latest research report, for the forecast period of 2020-2027. The research report consists of some distinguished insights for stakeholders for them to sustain their position and move to a higher market share. This exclusive research report is intended at providing rare and distinguished insights pertaining to the growth of the acute agitation and aggression treatment market, and offers information regarding the growth opportunities for market players. With the help of the insights mentioned in the research report, stakeholders in the acute agitation and aggression treatment market will be able to gain a brief outlook on its growth trajectory, which can help them in making well-informed strategies for their business growth.

The comprehensive business study analyzes and discusses Porter’s Five Forces, with a latent aim to provide the key growth strategies available in the acute agitation and aggression treatment market during the forecast period. This comprehensive guide provides key insights regarding the competition present in the acute agitation and aggression treatment market by identifying key competitors. This exclusive research report also offers information about the key strategies, financials, and notable developments of the acute agitation and aggression treatment market during the forecast period of 2020-2027. The acute agitation and aggression treatment market assessment has been conducted in terms of value (US$ Mn).

Key Questions Answered

This comprehensive research report analyzes and answers key questions concerning the growth of the acute agitation and aggression treatment market for the forecast period of 2020-2027. Some of the key questions answered in this research report are:

• What are the recent developments and key market shifts expected to be witnessed in the acute agitation and aggression treatment market during the forecast period?
• What are the key winning imperatives for leading and prominent players operating in the acute agitation and aggression treatment market?
• What are the key trends propelling the growth of the acute agitation and aggression treatment market?
• Which end user will exert a strong influence on the acute agitation and aggression treatment market?

Research Methodology

The research undertaken by VRR analysts consists of a robust approach in order to cull key insights regarding the growth of the acute agitation and aggression market for the forecast period of 2020-2027. Interviews as well as discussions with leading opinion leaders, market heads, vendors, distributors, industry experts, and key players were carried out in order to conduct primary research. In addition to this, our analysts also conducted a thorough secondary study of marketing collaterals, industry associations, company websites, and government statistics.